The stock of I-Mab ADR (IMAB) has seen a 28.04% increase in the past week, with a 30.48% gain in the past month, and a -8.67% decrease in the past quarter. The volatility ratio for the week is 11.62%, and the volatility levels for the past 30 days are at 7.46% for IMAB. The simple moving average for the past 20 days is 25.40% for IMAB’s stock, with a -15.36% simple moving average for the past 200 days.
Is It Worth Investing in I-Mab ADR (NASDAQ: IMAB) Right Now?
IMAB has 36-month beta value of 1.07. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMAB is 76.81M, and currently, short sellers hold a 0.79% ratio of that float. The average trading volume of IMAB on October 02, 2024 was 244.34K shares.
IMAB) stock’s latest price update
I-Mab ADR (NASDAQ: IMAB) has seen a rise in its stock price by 12.30 in relation to its previous close of 1.22. However, the company has experienced a 28.04% gain in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-16 that Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tolerated up to the highest study doses A Phase 1b study, evaluating givastomig in combination with standard-of-care treatment (nivolumab + chemotherapy (FOLFOX)) in front-line gastric cancer patients, is ongoing ROCKVILLE, Md., Sept. 16, 2024 /PRNewswire/ — I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced a poster presentation highlighting encouraging top-line results from its ongoing Phase 1 clinical study (NCT04900818) of givastomig, a novel first-in-class/ Claudin18.2 (CLDN18.2) and 4-1BB bispecific antibody immunostimulant, in patients with advanced cancers, especially gastric cancers (including gastroesophageal carcinoma, or GEC) at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain.
Analysts’ Opinion of IMAB
Many brokerage firms have already submitted their reports for IMAB stocks, with Siebert Williams Shank repeating the rating for IMAB by listing it as a “Buy.” The predicted price for IMAB in the upcoming period, according to Siebert Williams Shank is $96 based on the research report published on December 09, 2021 of the previous year 2021.
Needham gave a rating of “Buy” to IMAB, setting the target price at $75 in the report published on March 15th of the previous year.
IMAB Trading at 18.03% from the 50-Day Moving Average
After a stumble in the market that brought IMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.98% of loss for the given period.
Volatility was left at 7.46%, however, over the last 30 days, the volatility rate increased by 11.62%, as shares surge +24.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.39% lower at present.
During the last 5 trading sessions, IMAB rose by +22.43%, which changed the moving average for the period of 200-days by -13.82% in comparison to the 20-day moving average, which settled at $1.1055. In addition, I-Mab ADR saw -27.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMAB starting from KANNAN RAJ, who proposed sale 50,000 shares at the price of $1.39 back on Jul 26 ’24. After this action, KANNAN RAJ now owns shares of I-Mab ADR, valued at $69,500 using the latest closing price.
Stock Fundamentals for IMAB
Current profitability levels for the company are sitting at:
- -56.64 for the present operating margin
- 1.0 for the gross margin
The net margin for I-Mab ADR stands at -50.33. The total capital return value is set at -0.58. Equity return is now at value -39.60, with -30.80 for asset returns.
Currently, EBITDA for the company is -1.21 billion with net debt to EBITDA at 1.51. When we switch over and look at the enterprise to sales, we see a ratio of -16.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.50.
Conclusion
To put it simply, I-Mab ADR (IMAB) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
